Clinical Trial Update: Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous amino acid infusion to prevent contrast-induced nephropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy
• Kidney Injury

Drugs mentioned

• Intravenous amino acid infusion (amino acid solution)

Snippet

Sponsor: Queen's University | Conditions: Contrast Nephropathy, Renal Failure | Phase 2 | Status: WITHDRAWN